Real-World Enfortumab Vedotin ± Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma

These findings highlight the clinical relevance of EV ± P related toxicities, demonstrate the importance of accounting for immortal time bias in associations of these toxicities with survival, and add to a growing evidence base showing a survival association with skin toxicity in EV ± P treated patients. Future prospective studies are needed to evaluate skin toxicity as a favorable marker for survival.